# GSK4527226 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gsk4527226

> The next catalyst for GSK4527226, sponsored by GSK plc (GSK), is its topline data readout, Sep to Dec 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | GSK4527226 |
| Codes | GSK4527226 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Alzheimer's Disease](https://sec-api.dev/indications/alzheimer-s-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 14, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06079190 (Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06079190

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07105709 (Open-label Extension Study in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07105709

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07105709 (Open-label Extension Study in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07105709

## Same indication

- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [NBI-1117567](https://sec-api.dev/pdufa/nbi-1117567) (NBIX)
- [Remternetug](https://sec-api.dev/pdufa/remternetug) (LLY)
- [VHB937](https://sec-api.dev/pdufa/vhb937) (NVS)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

Calendar months: [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gsk4527226.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GSK4527226 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/gsk4527226

```bibtex
@misc{secapidev_pdufa_gsk4527226_20261116,
  title        = {GSK4527226 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gsk4527226}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gsk4527226_20261116","title":"GSK4527226 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gsk4527226","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
